Moxetumomab pasudotox for the treatment of relapsed and/or refractory hairy cell leukemia

References

• Bouroncle BA, Wiseman BK, Doan CA. Leukemic reticuloendotheliosis. Blood. 1958 Jul;13(7):609–630. PubMed PMID: 13560561; eng.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019 Jan;69(1):7–34. PubMed PMID: 30620402; eng.
   PubMed Web of Science ®Google Scholar
• Grever MR, Abdel-Wahab O, Andritsos LA, et al. Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia. Blood. 2017 Feb 2;129(5):553–560. PubMed PMID: 27903528; PubMed Central PMCID: PMCPMC5290982. eng.
   PubMed Web of Science ®Google Scholar
• Tiacci E, Trifonov V, Schiavoni G, et al. BRAF mutations in hairy-cell leukemia. N Engl J Med. 2011 Jun 16;364(24):2305–2315. PubMed PMID: 21663470; PubMed Central PMCID: PMCPMC3689585. eng.
   PubMed Web of Science ®Google Scholar
• Else M, Dearden CE, Matutes E, et al. Long-term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis. Br J Haematol. 2009 Jun;145(6):733–740. PubMed PMID: 19344416; eng.
   PubMed Web of Science ®Google Scholar
• Shao H, Calvo KR, Gronborg M, et al. Distinguishing hairy cell leukemia variant from hairy cell leukemia: development and validation of diagnostic criteria. Leuk Res. 2013 Apr;37(4):401–409. PubMed PMID: 23347903; PubMed Central PMCID: PMCPMC5575750. eng.
   PubMed Web of Science ®Google Scholar
• Thompson PA, Ravandi F. How I manage patients with hairy cell leukaemia. Br J Haematol. 2017 May;177(4):543–556. PubMed PMID: 28146266; eng.
   PubMed Web of Science ®Google Scholar
• Saven A, Burian C, Koziol JA, et al. Long-term follow-up of patients with hairy cell leukemia after cladribine treatment. Blood. 1998 Sep 15;92(6):1918–1926. PubMed PMID: 9731048; eng.
   PubMed Web of Science ®Google Scholar
• Goodman GR, Burian C, Koziol JA, et al. Extended follow-up of patients with hairy cell leukemia after treatment with cladribine. J Clin Oncol. 2003 Mar 1;21(5):891–896. PubMed PMID: 12610190; eng.
   PubMed Web of Science ®Google Scholar
• Madanat YF, Rybicki L, Radivoyevitch T, et al. Long-term outcomes of hairy cell leukemia treated with purine analogs: a comparison with the general population. Clin Lymphoma Myeloma Leuk. 2017 Dec;17(12):857–862. PubMed PMID: 28778620; eng.
   PubMed Web of Science ®Google Scholar
• Wheaton S, Tallman MS, Hakimian D, et al. Minimal residual disease may predict bone marrow relapse in patients with hairy cell leukemia treated with 2-chlorodeoxyadenosine. Blood. 1996 Feb 15;87(4):1556–1560. PubMed PMID: 8608247; eng.
   PubMed Web of Science ®Google Scholar
• Mhawech-Fauceglia P, Oberholzer M, Aschenafi S, et al. Potential predictive patterns of minimal residual disease detected by immunohistochemistry on bone marrow biopsy specimens during a long-term follow-up in patients treated with cladribine for hairy cell leukemia. Arch Pathol Lab Med. 2006 Mar;130(3):374–377. PubMed PMID: 16519567; eng.
   PubMed Web of Science ®Google Scholar
• Tallman MS. Implications of minimal residual disease in hairy cell leukemia after cladribine using immunohistochemistry and immunophenotyping. Leuk Lymphoma. 2011 Jun;52(Suppl 2):65–68. PubMed PMID: 21463116; eng.
   PubMedGoogle Scholar
• Ortiz-Maldonado V, Villamor N, Baumann T, et al. Is there a role for minimal residual disease monitoring in the management of patients with hairy-cell leukaemia? Br J Haematol. 2018 Oct;183(1):127–129. PubMed PMID: 28832940; eng.
   PubMed Web of Science ®Google Scholar
• Ravandi F, Jorgensen JL, O’Brien SM, et al. Eradication of minimal residual disease in hairy cell leukemia. Blood. 2006 Jun 15;107(12):4658–4662. PubMed PMID: 16497968; eng.
   PubMed Web of Science ®Google Scholar
• Sigal DS, Sharpe R, Burian C, et al. Very long-term eradication of minimal residual disease in patients with hairy cell leukemia after a single course of cladribine. Blood. 2010 Mar 11;115(10):1893–1896. PubMed PMID: 20056789; eng.
   PubMed Web of Science ®Google Scholar
• Rosenberg JD, Burian C, Waalen J, et al. Clinical characteristics and long-term outcome of young hairy cell leukemia patients treated with cladribine: a single-institution series. Blood. 2014 Jan 9;123(2):177–183. PubMed PMID: 24192579; eng.
   PubMed Web of Science ®Google Scholar
• Getta BM, Woo KM, Devlin S, et al. Treatment outcomes and secondary cancer incidence in young patients with hairy cell leukaemia. Br J Haematol. 2016 Nov;175(3):402–409. PubMed PMID: 27351754; PubMed Central PMCID: PMCPMC5539949. eng.
   PubMed Web of Science ®Google Scholar
• Cornet E, Tomowiak C, Tanguy-Schmidt A, et al. Long-term follow-up and second malignancies in 487 patients with hairy cell leukaemia. Br J Haematol. 2014 Aug;166(3):390–400. PubMed PMID: 24749839; eng.
   PubMed Web of Science ®Google Scholar
• Thomas DA, O’Brien S, Bueso-Ramos C, et al. Rituximab in relapsed or refractory hairy cell leukemia. Blood. 2003 Dec 1;102(12):3906–3911. PubMed PMID: 12816862; eng.
   PubMed Web of Science ®Google Scholar
• Nieva J, Bethel K, Saven A. Phase 2 study of rituximab in the treatment of cladribine-failed patients with hairy cell leukemia. Blood. 2003 Aug 1;102(3):810–813. PubMed PMID: 12663446; eng.
   PubMed Web of Science ®Google Scholar
• Ravandi F, O’Brien S, Jorgensen J, et al. Phase 2 study of cladribine followed by rituximab in patients with hairy cell leukemia. Blood. 2011 Oct 6;118(14):3818–3823. PubMed PMID: 21821712; PubMed Central PMCID: PMCPMC4081440. eng.
   PubMed Web of Science ®Google Scholar
• Wierda WG, Byrd JC, Abramson JS, et al. Hairy cell leukemia, version 2.2018, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2017 Nov;15(11):1414–1427. PubMed PMID: 29118233; eng.
   PubMed Web of Science ®Google Scholar
• Robak T, Matutes E, Catovsky D, et al. Hairy cell leukaemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015 Sep;26(Suppl 5):v100–7. PubMed PMID: 26269205; eng.
   PubMedGoogle Scholar
• Chihara D, Kantarjian H, O’Brien S, et al. Long-term durable remission by cladribine followed by rituximab in patients with hairy cell leukaemia: update of a phase II trial. Br J Haematol. 2016 Sep;174(5):760–766. PubMed PMID: 27301277; PubMed Central PMCID: PMCPMC5396841. eng.
   PubMed Web of Science ®Google Scholar
• Tiacci E, Park JH, De Carolis L, et al. Targeting mutant BRAF in relapsed or refractory hairy-cell leukemia. N Engl J Med. 2015 Oct 29;373(18):1733–1747. PubMed PMID: 26352686; PubMed Central PMCID: PMCPMC4811324. eng.
   PubMed Web of Science ®Google Scholar
• Tiacci E, De Carolis L, Simonetti E, et al. The BRAF inhibitor vemurafenib plus rituximab produces a high rate of deep and durable responses in relapsed/refractory hairy cell leukemia: updated results of a phase-2 trial. Hematol Oncol. 2019;37(S2):110–111.
   Google Scholar
• Kreitman RJ, Pastan I. Antibody fusion proteins: anti-CD22 recombinant immunotoxin moxetumomab pasudotox. Clin Cancer Res off J Am Assoc Cancer Res. 2011 Oct 15;17(20):6398–6405. PubMed PMID: 22003067; PubMed Central PMCID: PMCPMC3201735. eng.
   PubMed Web of Science ®Google Scholar
• Sullivan-Chang L, O’Donnell RT, Tuscano JM. Targeting CD22 in B-cell malignancies: current status and clinical outlook. BioDrugs. 2013 Aug;27(4):293–304. PubMed PMID: 23696252; eng.
   PubMed Web of Science ®Google Scholar
• Wayne AS, Fitzgerald DJ, Kreitman RJ, et al. Immunotoxins for leukemia. Blood. 2014 Apr 17;123(16):2470–2477. PubMed PMID: 24578503; PubMed Central PMCID: PMCPMC3990911. eng.
   PubMed Web of Science ®Google Scholar
• Kreitman RJ, Wilson WH, Bergeron K, et al. Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia. N Engl J Med. 2001 Jul 26;345(4):241–247. PubMed PMID: 11474661; eng.
   PubMed Web of Science ®Google Scholar
• Kreitman RJ, Squires DR, Stetler-Stevenson M, et al. Phase I trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with B-cell malignancies. J Clin Oncol. 2005 Sep 20;23(27):6719–6729. PubMed PMID: 16061911; eng.
   PubMed Web of Science ®Google Scholar
• Kreitman RJ, Stetler-Stevenson M, Margulies I, et al. Phase II trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with hairy cell leukemia. J Clin Oncol. 2009 Jun 20;27(18):2983–2990. PubMed PMID: 19414673; PubMed Central PMCID: PMCPMC2702232. eng.
   PubMed Web of Science ®Google Scholar
• Wayne AS, Kreitman RJ, Findley HW, et al. Anti-CD22 immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-positive hematologic malignancies of childhood: preclinical studies and phase I clinical trial. Clin Cancer Res off J Am Assoc Cancer Res. 2010 Mar 15;16(6):1894–1903. PubMed PMID: 20215554; PubMed Central PMCID: PMCPMC2840067. eng.
   PubMed Web of Science ®Google Scholar
• Salvatore G, Beers R, Margulies I, et al. Improved cytotoxic activity toward cell lines and fresh leukemia cells of a mutant anti-CD22 immunotoxin obtained by antibody phage display. Clin Cancer Res off J Am Assoc Cancer Res. 2002 Apr;8(4):995–1002. PubMed PMID: 11948105; eng.
   PubMed Web of Science ®Google Scholar
• Alderson RF, Kreitman RJ, Chen T, et al. CAT-8015: a second-generation pseudomonas exotoxin A-based immunotherapy targeting CD22-expressing hematologic malignancies. Clin Cancer Res off J Am Assoc Cancer Res. 2009 Feb 1;15(3):832–839. PubMed PMID: 19188153; PubMed Central PMCID: PMCPMC2742326. eng.
   PubMed Web of Science ®Google Scholar
• Kreitman RJ. Immunoconjugates and new molecular targets in hairy cell leukemia. Hematol Am Soc Hematol Educ Program. 2012;2012:660–666. PubMed PMID: 23233649; PubMed Central PMCID: PMCPMC6290482. eng.
   PubMedGoogle Scholar
• Kreitman RJ, Tallman MS, Robak T, et al. Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia. J Clin Oncol. 2012 May 20;30(15):1822–1828. PubMed PMID: 22355053; PubMed Central PMCID: PMCPMC3383181. eng.
   PubMed Web of Science ®Google Scholar
• Dhillon S. Moxetumomab pasudotox: first global approval. Drugs. 2018 Nov;78(16):1763–1767. PubMed PMID: 30357593; eng.
   PubMed Web of Science ®Google Scholar
• Kreitman RJ, Tallman MS, Robak T, et al. Minimal residual hairy cell leukemia eradication with moxetumomab pasudotox: phase 1 results and long-term follow-up. Blood. 2018 May 24;131(21):2331–2334. PubMed PMID: 29487070; PubMed Central PMCID: PMCPMC5969375. eng.
   PubMed Web of Science ®Google Scholar
• Kreitman RJ, Dearden C, Zinzani PL, et al. Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia. Leukemia. 2018 Aug;32(8):1768–1777. PubMed PMID: 30030507; PubMed Central PMCID: PMCPMC6087717. eng.
   PubMed Web of Science ®Google Scholar
• Jokiranta TS. HUS and atypical HUS. Blood. 2017 May 25;129(21):2847–2856. PubMed PMID: 28416508; PubMed Central PMCID: PMCPMC5445567. eng.
   PubMed Web of Science ®Google Scholar
• Siddall E, Khatri M, Radhakrishnan J. Capillary leak syndrome: etiologies, pathophysiology, and management. Kidney Int. 2017 Jul;92(1):37–46. PubMed PMID: 28318633; eng.
   PubMed Web of Science ®Google Scholar
• US prescription information on moxetumomab pasudotox. 2018 cited 2019 Feb 4. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761104s000lbl.pdf
   Google Scholar
• Bokori-Brown M, Metz J, Petrov PG, et al. Interactions between pseudomonas immunotoxins and the plasma membrane: implications for CAT-8015 immunotoxin therapy. Front Oncol. 2018;8:553. PubMed PMID: 30538953; PubMed Central PMCID: PMCPMC6277520. eng.
   PubMed Web of Science ®Google Scholar
• Pastan I, Onda M, Weldon J, et al. Immunotoxins with decreased immunogenicity and improved activity. Leuk Lymphoma. 2011 Jun;52(Suppl 2):87–90. PubMed PMID: 21504287; eng.
   PubMedGoogle Scholar
• Onda M, Beers R, Xiang L, et al. Recombinant immunotoxin against B-cell malignancies with no immunogenicity in mice by removal of B-cell epitopes. Proc Natl Acad Sci U S A. 2011 Apr 5;108(14):5742–5747. PubMed PMID: 21436054; PubMed Central PMCID: PMCPMC3078343. eng.
   PubMed Web of Science ®Google Scholar
• Chihara D, Arons E, Stetler-Stevenson M, et al. Randomized phase II study of cladribine with simultaneous or delayed rituximab in patients with untreated hairy cell leukemia. J Clin Oncol. 2019;37(15_suppl):7003.
   Google Scholar
• Burotto M, Stetler-Stevenson M, Arons E, et al. Bendamustine and rituximab in relapsed and refractory hairy cell leukemia. Clin Cancer Res off J Am Assoc Cancer Res. 2013 Nov 15;19(22):6313–6321. PubMed PMID: 24097860; PubMed Central PMCID: PMCPMC3861900. eng.
   PubMed Web of Science ®Google Scholar
• Gerrie AS, Zypchen LN, Connors JM. Fludarabine and rituximab for relapsed or refractory hairy cell leukemia. Blood. 2012 Mar 1;119(9):1988–1991. PubMed PMID: 22223825; eng.
   PubMed Web of Science ®Google Scholar
• Seymour JF, Estey EH, Keating MJ, et al. Response to interferon-alpha in patients with hairy cell leukemia relapsing after treatment with 2-chlorodeoxyadenosine. Leukemia. 1995 May;9(5):929–932. PubMed PMID: 7769859; eng.
   PubMed Web of Science ®Google Scholar
• Janus A, Robak T. Moxetumomab pasudotox for the treatment of hairy cell leukemia. Expert Opin Biol Ther. 2019 Jun;19(6):501–508. PubMed PMID: 31045462; eng.
   PubMed Web of Science ®Google Scholar